Storia in 6 fonti

Argenx to buy Forte Biosciences for $2.2B

Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 g fa

Argenx to buy Forte Biosciences for $2.2B

Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.

originale

Timeline cronologica

lunedì 27 luglio 2026·morningstar.com
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
lunedì 27 luglio 2026·statnews.com
Argenx to buy Forte Biosciences for $2.2B
Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.

benzinga.com

16 h fa

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover - argenx (NASDAQ:ARGX), Forte Bios

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.

Leggi questa versione → originale

endpoints.news21 h fa

Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B

Argenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases.

Leggi questa versione → originale

valor.globo.com20 h fa

Argenx fecha acordo para comprar a Forte Biosciences por US$ 2,2 bilhões

O negócio permite adicionar ao portfólio o medicamento experimental FB102, da Forte, para o qual a empresa enxerga potencial de atender a doenças com alta necessidade não atendida e que carecem de novos tratamentos

Leggi questa versione → originale

lecho.be1 g fa

Argenx rachète une société américaine de biotechnologie pour 2,2 milliards de dollars

Grâce à sa confortable trésorerie, argenx reprend Forte Biosciences, une société américaine également spécialisée dans les maladies immunitaires complexes. Une opération à 2,2 milliards de dollars.

Leggi questa versione → originale

morningstar.com1 g fa

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its…

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Leggi questa versione → originale

lunedì 27 luglio 2026·

lecho.be

Argenx rachète une société américaine de biotechnologie pour 2,2 milliards de dollars

Grâce à sa confortable trésorerie, argenx reprend Forte Biosciences, une société américaine également spécialisée dans les maladies immunitaires complexes. Une opération à 2,2…

lunedì 27 luglio 2026·

lecho.be

Des analystes valident le rachat de Forte par argenx, le marché moins

En vue d'élargir son pipeline dans l'immunologie, argenx met la main sur une biotech américaine pour 2,2 milliards de dollars. Le marché se montre circonspect alors que des…

lunedì 27 luglio 2026·

endpoints.news

Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B

Argenx will spend $2.2 billion to buy Forte Biosciences and its anti-CD122 monoclonal antibody that’s under investigation for autoimmune diseases.

lunedì 27 luglio 2026·

valor.globo.com

Argenx fecha acordo para comprar a Forte Biosciences por US$ 2,2 bilhões

O negócio permite adicionar ao portfólio o medicamento experimental FB102, da Forte, para o qual a empresa enxerga potencial de atender a doenças com alta necessidade não atendida…

lunedì 27 luglio 2026·

benzinga.com

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover - argenx (NASDAQ:ARGX), Forte Bios

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.